volume 271, issue 1-2, P1-4 2004
DOI: 10.1016/j.ijpharm.2003.11.031
View full text
|
|
Share

Abstract: Even today the treatment outcome of tuberculosis is questionable due to variable bioavailability of rifampicin, which was discovered four decades back. In this manuscript, results of bioequivalence trials reported are presented in the form of a figure that provides a comprehensive look at the rifampicin bioavailability literature, provides understanding of the problem and clears 'myths and assumptions' regarding rifampicin bioavailability from fixed-dose combination (FDC) formulations. It was found that FDCs o…

expand abstract